Dicerna Finds RNAi-Savvy Partner in Kyowa for Cancer Drug Program
January 07, 2010
Dicerna Finds RNAi-Savvy Partner in Kyowa for Cancer Drug Program
Under the terms of the arrangement, Dicerna will receive from Kyowa $4 million up front and up to $120 million in research funding and milestones in exchange for the exclusive rights to an undisclosed cancer target. Additional targets may be added to the arrangement under similar terms.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dicerna, Kyowa Reach In Vivo Activity Milestone in Cancer Collaboration
August 9, 2012 / Gene Silencing News - Kyowa Selects Second Cancer Drug Candidate under Dicerna Partnership
January 3, 2013 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Dicerna Selects Target, Delivery Tech for First Clinical Candidate
May 24, 2012 / Gene Silencing News - Dicerna Aims for Partnership in '12, IND in '13
December 22, 2011 / Gene Silencing News